Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-18

FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

The FDA approved Actavis Pharma's supplemental application to market a generic fluvoxamine maleate product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fluvoxamine Maleate (Fluvoxamine maleate)

Snippet

SUPPL AP for FLUVOXAMINE MALEATE (FLUVOXAMINE MALEATE)